Table 1. Characteristics of the study participants.
| No of participants (number of women, %) | 414 (124, 30) |
| Age, range in years (median) | 19–76 (40) |
| Transmission route | |
| Intravenous drug use, n (%) | 134 (32.4) |
| Sexual contact, n (%) | 270 (65.2) |
| MSM contact, n (%) | 124 (30) |
| Unknown, n (%) | 10 (2.4) |
| HCV-positive, n (%) | 220 (53.3%) |
| Lymphocyte CD4+ T cell count at baseline # | |
| range (cells/μl) | 0–1707 |
| median (IQR) (cells/μl) | 280.5 (94.0–486) |
| Nadir lymphocyte CD4+ T cell count $ | |
| range (cells/μl) | 0–1189 |
| median (IQR) (cells/μl) | 180 (63.5–371) |
| HIV viral load at baseline * | |
| range log copies/ml | 1.4–7.4 |
| mean log copies/ml (SD) | 4.8 (0.99) |
| HIV infection stage at genotyping according to CDC, n (%) | |
| A | 140 (33.8) |
| B | 138 (33.3) |
| C | 124 (30) |
| no data | 12 (2.9) |
| HIV-1 subtype B @ , n (%) | 264 (74.4) |
| HIV-1 non-B variants @ , n (%) | 91 (25.6) |
# available for 408 cases.
$available for 384 cases.
*available for 414 cases.
@ subtype available for 355 cases.